These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36506552)

  • 1. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS.
    Feng Z; Li X; Tong WK; He Q; Zhu X; Xiang X; Tang Z
    Front Pharmacol; 2022; 13():894685. PubMed ID: 36506552
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
    Ji C; Bai J; Zhou J; Zou Y; Yu M
    Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS.
    Shi X; Qiao Y; Yang Y; Wang N; Zhang Y; Shi S; Shen G; Jia X
    Expert Opin Drug Saf; 2024 Sep; ():1-6. PubMed ID: 39323041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.
    Goldman A; Raschi E; Cukierman-Yaffe T; Dankner R; Shouval R; Shechter M; Ben-Zvi I; Gerstein HC; Maor E
    Eur J Prev Cardiol; 2022 Jul; 29(9):1334-1342. PubMed ID: 34897409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.
    di Mauro G; Zinzi A; Scavone C; Mascolo A; Gaio M; Sportiello L; Ferrajolo C; Rafaniello C; Rossi F; Capuano A
    Drug Saf; 2021 Mar; 44(3):337-349. PubMed ID: 33351170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis.
    Zhao X; Wu J; Zhu S
    Br J Clin Pharmacol; 2023 Feb; 89(2):458-469. PubMed ID: 35973681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Ding L; Chen C; Yang Y; Fang J; Cao L; Liu Y
    Cardiovasc Ther; 2022; 2022():9866486. PubMed ID: 35140810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy-related adverse events associated with statins: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS).
    Wu T; Shi Y; Zhu B; Li D; Li Z; Zhao Z; Zhang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):313-321. PubMed ID: 37612600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.
    Liu H
    Front Pharmacol; 2024; 15():1353848. PubMed ID: 39148544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study.
    Deng Z; Liu J; Gong H; Cai X; Xiao H; Gao W
    CNS Neurosci Ther; 2024 Apr; 30(4):e14522. PubMed ID: 37950531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
    Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
    J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
    Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
    Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis.
    Gouverneur A; Sanchez-Pena P; Veyrac G; Salem JE; Bégaud B; Bezin J
    Cardiovasc Drugs Ther; 2023 Apr; 37(2):271-276. PubMed ID: 34436707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups.
    He Y; Guan X; Zhang Y; Zhu Z; Zhang Y; Feng Y; Li X
    Expert Opin Drug Saf; 2024 Dec; 23(12):1561-1569. PubMed ID: 38676389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
    Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
    BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.